Raspaglio Giuseppina, Ferlini Cristiano, Mozzetti Simona, Prislei Silvia, Gallo Daniela, Das Nandita, Scambia Giovanni
Laboratory of Antineoplastic Pharmacology, Department of Obstetrics and Gynecology, Catholic University of the Sacred Heart, Rome, Italy.
Biochem Pharmacol. 2005 Jan 1;69(1):113-21. doi: 10.1016/j.bcp.2004.09.004.
During a cellular screening of thiocolchicine analogs, thiocolchicine dimers resulted particularly active in cisplatin-resistant A2780-CIS cells. In order to discover by which mechanism(s) thiocolchicine dimers overcame cisplatin resistance, p53, p21waf1 and MLH1 were assessed by Western blot. Results pointed out that, when combined with cisplatin, dimers increased the amount of all the three proteins with respect to the levels obtained by single drug exposure, thereby suggesting an interference in the process of repair of the cisplatin-induced DNA lesions. Moreover, in isolated nuclei drugs were able to produce DNA breaks, as demonstrated by Comet assay, thereby proving that the compounds were able to target cell nucleus independently from microtubules. Since Topo-I (topoisomerase I) is directly involved in the DNA repair and such activity is overexpressed in cisplatin-resistant cells, Topo-I was investigated as a potential target. Using DNA relaxation assay, thiocolchicine dimers inhibited Topo-I, a property not shared by thiocolchicine. At variance with camptothecin, dimers did not produce cleavable complexes, thereby indicating that Topo-I inhibition occurs upstream of the religation step. To assess the mechanism of inhibition, an electrophoretic mobility shift assay between DNA and Topo-I was performed and revealed that thiocolchicine dimers specifically interfere with binding of Topo-I to DNA. The interference is specific since the same compounds did not modulate DNase activity and did not act as intercalating agents in the DNA unwinding assay. Finally, behaviour of dimers as spindle poisons was investigated and no relevant changes with respect to thiocolchicine in terms of interaction with microtubules were found.
在对硫代秋水仙碱类似物进行细胞筛选时,硫代秋水仙碱二聚体在顺铂耐药的A2780 - CIS细胞中表现出特别高的活性。为了探究硫代秋水仙碱二聚体克服顺铂耐药性的机制,通过蛋白质免疫印迹法评估了p53、p21waf1和MLH1。结果表明,当与顺铂联合使用时,二聚体相对于单一药物处理所获得的水平,增加了所有这三种蛋白质的量,从而提示其对顺铂诱导的DNA损伤修复过程产生了干扰。此外,彗星试验证明,在分离的细胞核中,这些药物能够产生DNA断裂,从而证明这些化合物能够独立于微管靶向细胞核。由于拓扑异构酶I(Topo - I)直接参与DNA修复,且这种活性在顺铂耐药细胞中过表达,因此将Topo - I作为潜在靶点进行了研究。使用DNA松弛试验,发现硫代秋水仙碱二聚体能够抑制Topo - I,而硫代秋水仙碱则没有这种特性。与喜树碱不同,二聚体不会产生可切割复合物,这表明Topo - I抑制发生在重新连接步骤的上游。为了评估抑制机制,进行了DNA与Topo - I之间的电泳迁移率变动分析,结果显示硫代秋水仙碱二聚体特异性干扰Topo - I与DNA的结合。这种干扰是特异性的,因为相同的化合物不会调节DNase活性,并且在DNA解旋试验中也不作为嵌入剂起作用。最后,研究了二聚体作为纺锤体毒物的行为,发现在与微管相互作用方面,与硫代秋水仙碱相比没有相关变化。